Dr. Agarwal's Eye [DRAGARWQ] vs Apollo Hospitals [APOLLOHOSP] Detailed Stock Comparison

Dr. Agarwal's Eye
BSE
Loading...

Apollo Hospitals
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Dr. Agarwal's Eye wins in 12 metrics, Apollo Hospitals wins in 8 metrics, with 0 ties. Dr. Agarwal's Eye appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Dr. Agarwal's Eye | Apollo Hospitals | Better |
---|---|---|---|
P/E Ratio (TTM) | 36.63 | 71.43 | Dr. Agarwal's Eye |
Price-to-Book Ratio | 10.09 | 13.69 | Dr. Agarwal's Eye |
Debt-to-Equity Ratio | 158.94 | 90.89 | Apollo Hospitals |
PEG Ratio | 1.64 | 1.71 | Dr. Agarwal's Eye |
EV/EBITDA | 18.64 | 40.36 | Dr. Agarwal's Eye |
Profit Margin (TTM) | 13.96% | 6.98% | Dr. Agarwal's Eye |
Operating Margin (TTM) | 22.71% | 10.91% | Dr. Agarwal's Eye |
EBITDA Margin (TTM) | 22.71% | 10.91% | Dr. Agarwal's Eye |
Return on Equity | 26.07% | 16.71% | Dr. Agarwal's Eye |
Return on Assets (TTM) | 8.91% | 7.00% | Dr. Agarwal's Eye |
Free Cash Flow (TTM) | $-83.80M | $4.24B | Apollo Hospitals |
Dividend Yield | 0.11% | 0.27% | Apollo Hospitals |
1-Year Return | 13.88% | 16.97% | Apollo Hospitals |
Price-to-Sales Ratio (TTM) | 5.11 | 4.99 | Apollo Hospitals |
Enterprise Value | $24.24B | $1,187.56B | Apollo Hospitals |
EV/Revenue Ratio | 5.85 | 5.27 | Apollo Hospitals |
Gross Profit Margin (TTM) | 58.67% | 47.83% | Dr. Agarwal's Eye |
Revenue per Share (TTM) | $881 | $1,568 | Apollo Hospitals |
Earnings per Share (Diluted) | $122.87 | $109.50 | Dr. Agarwal's Eye |
Beta (Stock Volatility) | -0.35 | 0.16 | Dr. Agarwal's Eye |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Dr. Agarwal's Eye vs Apollo Hospitals Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Dr. Agarwal's Eye | -0.51% | 3.11% | 1.38% | 8.24% | 10.72% | -30.48% |
Apollo Hospitals | 0.01% | 9.09% | 8.33% | 13.08% | 24.73% | 6.13% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Dr. Agarwal's Eye | 13.88% | 469.51% | 1,862.42% | 3,004.00% | 5,456.54% | 10,342.69% |
Apollo Hospitals | 16.97% | 89.14% | 366.26% | 500.57% | 1,823.02% | 4,128.29% |
Performance & Financial Health Analysis: Dr. Agarwal's Eye vs Apollo Hospitals
Metric | DRAGARWQ | APOLLOHOSP |
---|---|---|
Market Information | ||
Market Cap | ₹21.15B | ₹1.12T |
Market Cap Category | Small cap | Large cap |
10 Day Avg. Volume | 1,335 | 559,600 |
90 Day Avg. Volume | 1,326 | 449,857 |
Last Close | ₹4,477.75 | ₹7,822.50 |
52 Week Range | ₹3,500.00 - ₹7,300.00 | ₹6,001.00 - ₹7,917.50 |
% from 52W High | -38.66% | -1.20% |
All-Time High | ₹7,300.00 (Dec 30, 2024) | ₹552,030.00 (Nov 20, 2023) |
% from All-Time High | -38.66% | -98.58% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.17% | 0.15% |
Quarterly Earnings Growth | 0.22% | 0.42% |
Financial Health | ||
Profit Margin (TTM) | 0.14% | 0.07% |
Operating Margin (TTM) | 0.23% | 0.11% |
Return on Equity (TTM) | 0.26% | 0.17% |
Debt to Equity (MRQ) | 158.94 | 90.89 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹445.96 | ₹571.15 |
Cash per Share (MRQ) | ₹52.76 | ₹139.82 |
Operating Cash Flow (TTM) | ₹756.10M | ₹14.57B |
Levered Free Cash Flow (TTM) | ₹546.50M | ₹14.46B |
Dividends | ||
Last 12-Month Dividend Yield | 0.11% | 0.27% |
Last 12-Month Dividend | ₹5.00 | ₹19.00 |
Valuation & Enterprise Metrics Analysis: Dr. Agarwal's Eye vs Apollo Hospitals
Metric | DRAGARWQ | APOLLOHOSP |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 36.63 | 71.43 |
Forward P/E | 463.05 | 95.85 |
PEG Ratio | 1.64 | 1.71 |
Price to Sales (TTM) | 5.11 | 4.99 |
Price to Book (MRQ) | 10.09 | 13.69 |
Market Capitalization | ||
Market Capitalization | ₹21.15B | ₹1.12T |
Enterprise Value | ₹24.24B | ₹1.19T |
Enterprise Value Metrics | ||
Enterprise to Revenue | 5.85 | 5.27 |
Enterprise to EBITDA | 18.64 | 40.36 |
Risk & Other Metrics | ||
Beta | -0.35 | 0.16 |
Book Value per Share (MRQ) | ₹445.96 | ₹571.15 |
Financial Statements Comparison: Dr. Agarwal's Eye vs Apollo Hospitals
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | DRAGARWQ | APOLLOHOSP |
---|---|---|
Revenue/Sales | ₹1.17B | ₹58.42B |
Cost of Goods Sold | ₹483.20M | ₹30.48B |
Gross Profit | ₹686.00M | ₹27.95B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹265.50M | ₹6.37B |
EBITDA | ₹379.30M | ₹9.06B |
Pre-Tax Income | ₹231.90M | ₹5.83B |
Income Tax | ₹59.30M | ₹1.42B |
Net Income (Profit) | ₹172.60M | ₹4.41B |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | DRAGARWQ | APOLLOHOSP |
---|---|---|
Cash & Equivalents | ₹111.60M | ₹5.78B |
Total Current Assets | ₹559.40M | ₹70.29B |
Total Current Liabilities | ₹869.80M | ₹45.79B |
Long-Term Debt | ₹3.06B | ₹43.86B |
Total Shareholders Equity | ₹2.10B | ₹86.53B |
Retained Earnings | N/A | ₹39.41B |
Property, Plant & Equipment | ₹3.65B | ₹39.33B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | DRAGARWQ | APOLLOHOSP |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | DRAGARWQ | APOLLOHOSP |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 1,335 | 559,600 |
Average Daily Volume (90 Day) | 1,326 | 449,857 |
Shares Outstanding | 4.70M | 143.78M |
Float Shares | 1.11M | 98.21M |
% Held by Insiders | 0.78% | 0.30% |
% Held by Institutions | 0.02% | 0.48% |
Dividend Analysis & Yield Comparison: Dr. Agarwal's Eye vs Apollo Hospitals
Metric | DRAGARWQ | APOLLOHOSP |
---|---|---|
Last 12-Month Dividend | ₹5.00 | ₹19.00 |
Last 12-Month Dividend Yield | 0.11% | 0.27% |
3-Year Avg Annual Dividend | ₹4.50 | ₹20.25 |
3-Year Avg Dividend Yield | 0.12% | 0.17% |
3-Year Total Dividends | ₹13.50 | ₹60.75 |
Ex-Dividend Date | Nov 08, 2024 | Feb 14, 2025 |